research Controversies: Is Finasteride Safety Data Adequately Reported in Published Trials?
Finasteride safety data in trials may be underreported or misrepresented.
Search
for
Sort by
Research
30 / 1000+ resultsresearch Real-world safety of ixekizumab: a disproportionality analysis using the FDA adverse event reporting system and the VigiAccess databases
Ixekizumab has known and some unexpected side effects.
research Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions
Teriflunomide is safe and tolerable for treating relapsing-remitting multiple sclerosis, with manageable side effects.
research AB0597 Comparative analysis of safety data of four treatment regimens in early rheumatoid arthritis patients
Methotrexate plus prednisolone had the fewest serious side effects.
research A10.09 Safety data of four treatment regimens in early rheumatoid arthritis patients
All four treatments for early rheumatoid arthritis had similar and mostly mild side effects.
research Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study
Healthcare claims databases can help monitor drug safety, but may report adverse events differently than direct surveillance.
research SAFETY AND TOLERABILITY OF ANTIEPILEPTIC DRUGS AT WOMEN WITH EPILEPSY (DATA OF SVT. LUKA’S INSTITUTE OF CHILD NEUROLOGY AND EPILEPSY)
Antiepileptic drugs can cause side effects like menstrual problems and infertility in women with epilepsy, but most pregnancies result in healthy babies, with newer drugs being safer.
research Risk of Safety Events in Vitiligo Patients: A Retrospective Real‐World Data Study in the US
Vitiligo patients have higher risks of autoimmune diseases, infections, and skin cancer.
research Is the Safety of Finasteride Correlated With Its Route of Administration: Topical Versus Oral? A Pharmacovigilance Study With Data From the United States Food and Drug Administration Adverse Event Reporting System
Topical finasteride may be safer than oral finasteride, but more research is needed.
research Safety profile of ipilimumab in elderly patients: a disproportionate analysis based on the FDA Adverse Event Reporting System database
This study analyzed 18,698 adverse event reports from the FAERS database to assess the safety of ipilimumab in elderly patients (≥65 years). It identified 245 positive signals of adverse events, including common ones like malignant neoplasm progression, diarrhea, and colitis, as well as less common ones not listed on the drug label, such as orchitis and alopecia areata. Approximately 40% of adverse events occurred within one month of starting treatment, with a median onset time of 42 days. Skin-related adverse events had the shortest onset time, while endocrine-related events had the longest. The study highlights the importance of monitoring gastrointestinal and endocrine toxicities in elderly patients using ipilimumab.
research Safety and tolerability of antiepileptic drugs in women with epilepsy (literature review and own data)
Some epilepsy drugs can cause reproductive and cosmetic side effects in women and affect pregnancy, but most women still have healthy babies.
research Assessing the real-world safety of tralokinumab for atopic dermatitis: insights from a comprehensive analysis of FAERS data
Tralokinumab for atopic dermatitis may cause side effects like dizziness, headache, nausea, hair loss, and acne.
research Economic analysis of finasteride: A model-based approach using data from the Proscar long-term efficacy and safety study
Finasteride is a cost-effective option for treating BPH, reducing risk of urinary issues and surgery.
research Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
Baricitinib, a drug for rheumatoid arthritis, atopic dermatitis, and alopecia areata, is generally safe with low risk of major side effects, even in patients with risk factors. It's also effective in promoting hair regrowth in alopecia areata patients.
research Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database
Biologics for severe asthma have known side effects, but some new risks need more study.
research Effectiveness and Safety of Topical Finasteride for Male Androgenetic Alopecia: Real World Data
Topical finasteride effectively and safely improves hair growth in men with androgenetic alopecia.
research Safety of low‐dose oral minoxidil treatment for hair loss. A systematic review and pooled‐analysis of individual patient data
Low-dose oral minoxidil is a safe treatment for hair loss, with the main side effect being excessive hair growth. Other side effects like foot swelling, low blood pressure when standing, and heart rate changes are rare.
research Disproportionality analysis comparing safety profiles of sonidegib and vismodegib based on the FAERS database
Sonidegib and vismodegib have different side effects and reporting patterns.
research Long‐term efficacy and safety of dutasteride 0.5 mg in Korean men with androgenetic alopecia: 5‐year data demonstrating clinical improvement with sustained efficacy
Dutasteride 0.5 mg is safe and effective for long-term use in Korean men with hair loss.
research Efficacy and safety of fremanezumab for migraine prophylaxis in patients with at least three previous preventive failures: Prospective, multicenter, real‐world data from a Greek registry
Fremanezumab effectively reduces migraines and improves quality of life with mild side effects.
research Effectiveness and Safety of Resilient Hyaluronic Acid (RHA) Dermal Fillers for the Correction of Moderate-to-Severe Nasolabial Folds in People of Color: Post Hoc Subgroup Analyses of US Pivotal Clinical Data
RHA fillers are effective and safe for treating nasolabial folds in people of color.
research 42889 Long-term efficacy and safety of dutasteride in Korean men with androgenetic alopecia: 5-year follow-up data exhibiting clinical improvement with sustained efficacy
Dutasteride is safe and effective long-term for male hair loss.
research 42276 Long-Term Safety of Ixekizumab Treatment in Adult Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: A Post-hoc Analysis of End-Of-Study Program Data Relating to Major Adverse Cardiovascular Events
Ixekizumab is safe for long-term use with low rates of major heart-related events.
research What’s new in androgenetic alopecia: approvals, long-term safety data, cancer risk and treatment options for women.
research Why Do Promising Therapies Stall in Development and How Can We Move Them Forward?
Most drugs fail to reach the market, but understanding their properties and using strategies like early toxicity tests and drug repurposing can help advance their development.
research Safety and efficacy of transdermal testosterone for treatment of hypoactive sexual desire disorder
Transdermal testosterone can improve sexual desire in postmenopausal women but lacks long-term safety data and is not FDA-approved for this use.
research Janus kinase inhibitors for alopecia areata: a review of clinical data
JAK inhibitors effectively and safely treat alopecia areata with few serious side effects.
research Comments on “Maternal–fetal safety evaluation of an aqueous extract of Casearia sylvestris [AECS ] leaves in rats” (Nagaoka et al., 2023 [DOI : 10.1002/bdr2.2257])
The commentary stresses the importance of using historical control data and proper interpretation in evaluating developmental toxicity.
research Final Report on the Safety Assessment of Hypericum Perforatum Extract and Hypericum Perforatum Oil
St. John's Wort extract and oil safety in cosmetics is unclear; more data needed on photosensitization, toxicity, and human irritation.
research Mining and analysis of adverse event signals of isotretinoin based on the real-world data of FAERS database
Isotretinoin has many serious side effects, including some new ones, needing better safety measures and updated labels.